Figures & data
Figure 1 Percentage of patients (95% CI) achieving HIV RNA < 50 copies/mL.
Copyright © Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. All Rights Reserved.
*P-value derived from a logistic regression model adjusted for baseline HIV RNA level (log10), first enfuvirtide use in optimized background therapy (OBT), first darunavir use in OBT, active protease inhibitors in OBT.
Figure 2 Change from baseline in CD4 cell count (cells/mm3).
Copyright © Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. All Rights Reserved.
*P-value derived from mixed-effects model adjusted for: baseline CD4 count, stratum, treatment, visit, interactions between visit and previous variables.
Abbreviation: OBT, optimized background therapy.
Figure 3 Percentage of patients with HIV RNA < 50 copies/mL at week 96 by genotypics sensitivity score (GSS).a
Copyright © Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., USA. All Rights Reserved.
*Virologic failures carried forward.
Abbreviation: OBT, optimized background therapy.
